UY28910A1 - Prodrogas de estriol y estetrol - Google Patents

Prodrogas de estriol y estetrol

Info

Publication number
UY28910A1
UY28910A1 UY28910A UY28910A UY28910A1 UY 28910 A1 UY28910 A1 UY 28910A1 UY 28910 A UY28910 A UY 28910A UY 28910 A UY28910 A UY 28910A UY 28910 A1 UY28910 A1 UY 28910A1
Authority
UY
Uruguay
Prior art keywords
estetrol
estriol
products
prodrugs
compounds
Prior art date
Application number
UY28910A
Other languages
English (en)
Spanish (es)
Inventor
Alexander Hillisch
Ralf Wyrwa
Peter Droescher
Walter Elger
Gudrun Reddersen
Sven Ring Birgitt Schneider
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34969311&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY28910(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of UY28910A1 publication Critical patent/UY28910A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UY28910A 2004-05-21 2005-05-19 Prodrogas de estriol y estetrol UY28910A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004025985A DE102004025985A1 (de) 2004-05-21 2004-05-21 Estriol- und Estetrol-Prodrugs

Publications (1)

Publication Number Publication Date
UY28910A1 true UY28910A1 (es) 2005-12-30

Family

ID=34969311

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28910A UY28910A1 (es) 2004-05-21 2005-05-19 Prodrogas de estriol y estetrol

Country Status (11)

Country Link
EP (1) EP1747231A1 (fr)
JP (1) JP2007538027A (fr)
AR (1) AR049108A1 (fr)
DE (1) DE102004025985A1 (fr)
GT (1) GT200500120A (fr)
PA (1) PA8633801A1 (fr)
PE (1) PE20060314A1 (fr)
SV (1) SV2006002122A (fr)
TW (1) TW200612962A (fr)
UY (1) UY28910A1 (fr)
WO (1) WO2005113576A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10027887A1 (de) 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US7534780B2 (en) 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
DE102004025966A1 (de) * 2004-05-21 2005-12-15 Schering Ag Estradiol-Prodrugs
DE102005057224A1 (de) * 2005-11-29 2007-05-31 Bayer Schering Pharma Ag Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE102005057408A1 (de) * 2005-11-30 2007-05-31 Bayer Schering Pharma Ag Sulfamoylsulfonat-Prodrugs
CN100396693C (zh) * 2006-11-08 2008-06-25 浙江大学 1,4-孕二烯-16β-甲基-17α,21-二羟基物的制备方法
CN102079771B (zh) * 2010-12-10 2012-10-03 郑州大学 具有抗肿瘤活性的雌甾氨基酸酯化合物及其合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1238739A (fr) * 1958-08-04 1960-08-19 Chimiotherapie Lab Franc Procédé de préparation de dérivés hydrosolubles de testostérone
FR8290M (fr) * 1968-12-31 1970-11-09 Rech Chimiques Et Ind Mar Lab
US5001234A (en) * 1987-04-16 1991-03-19 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
US5116828A (en) * 1989-10-26 1992-05-26 Nippon Zoki Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of osteoporosis
US5571933A (en) * 1994-11-17 1996-11-05 Duquesne University Of The Holy Ghost Derivatives of estra 1,3,5(10)triene-17-one, 3-amino compounds and their use
DE19712488A1 (de) * 1997-03-25 1998-10-01 Knoell Hans Forschung Ev Steroidsulfamate, Verfahren zu ihrer Herstellung und Anwendung derselben
JPWO2001081364A1 (ja) * 2000-04-24 2004-01-08 協和醗酵工業株式会社 エストラ−１，３，５（１０）−トリエン誘導体
DE10027887A1 (de) * 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
GB0015876D0 (en) * 2000-06-28 2000-08-23 Novartis Ag Organic compounds
GB0316290D0 (en) * 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
TWI331154B (en) * 2003-11-12 2010-10-01 Solvay Pharm Gmbh Novel 17-hydroxysteroid dehydrogenase type i inhibitors
DE102004025966A1 (de) * 2004-05-21 2005-12-15 Schering Ag Estradiol-Prodrugs

Also Published As

Publication number Publication date
TW200612962A (en) 2006-05-01
EP1747231A1 (fr) 2007-01-31
SV2006002122A (es) 2006-05-09
DE102004025985A1 (de) 2005-12-15
WO2005113576A1 (fr) 2005-12-01
AR049108A1 (es) 2006-06-28
PE20060314A1 (es) 2006-05-25
PA8633801A1 (es) 2006-03-24
JP2007538027A (ja) 2007-12-27
GT200500120A (es) 2006-01-24

Similar Documents

Publication Publication Date Title
UY28909A1 (es) Prodrogas de estradiol
UY28910A1 (es) Prodrogas de estriol y estetrol
UY30711A1 (es) Nuevos derivados de 1,4-benzotiepina-1, 1-cioxido, método para su preparacion, productos farmacéuticos que comprenden estos compuestos y su uso.-
UY30824A1 (es) Nuevos derivados de idazolil éster o amida, composiciones farmacéuticas conteniéndolas, procesos de preparacion y aplicaciones.
AR030707A1 (es) 9-ALFA-CLORO-6-ALFA-FLUOR-17-ALFA-HIDROXI-16-METIL-17-BETA-METOXICARBONIL-ANDROST-1,4-DIENOS, UN PROCESO PARA SU PREPARACIoN , COMPOSICION FARMACEUTICA, Y EL USO DEL MISMO PARA LA FABRICACION DE MEDICAMENTO
BRPI0712631A8 (pt) compostos, processos para a preparação de um composto, composição farmacêutica, uso de um composto e combinações
UY29002A1 (es) Nuevos derivados de hidantoína, procesos parasu preparación, composiciones farmacéuticas que los contienen y su uso en terapia
AR025052A1 (es) Derivados de 2-dialquilaminoalquilbifenilo sustituidos, procedimiento para su preparacion, medicamentos que contienen estos compuestos y el uso de estoscompuestos para la preparacion de medicamentos.
CU23415B7 (es) Derivados de 2,6- quinolinilo y 2,6- naftilo, procesos para su preparación y sus usos
CU20110185A7 (es) Nuevos derivados de compuestos de [3,2-c]pirazol esteroidal con actividad glucocorticoide
UY28911A1 (es) Profármacos de esteroides con acción androgénica
UY30356A1 (es) Derivados de 3-halo-n-(2.(4-fluorofenil)-4-oxobutil)-n-metil-5-(trifluorometil)benzamida y composiciones de los mismos.
ECSP088472A (es) Derivados de 9-cloro-15-desoxiprostaglandina, procesos para su preparación y su uso como medicamento
GT200600272A (es) Moduladores no esteroides de receptores de progesterona
UY27133A1 (es) 11beta-halogenesteroides, su obtención y uso para la preparación de medicamentos y preparados farmacéuticos que contienen 11 beta-halogenesteroides
ECSP088481A (es) Prodrogas de sustancias er-beta-selectivas, procesos para su preparación y composiciones farmacéuticas que comprenden estos productos
UY26507A1 (es) Bases de mannich de 1-naftol y 2-naftol sustituidos, procedimiento para su preparación, medicamentos que contienen estos compuestos, así como el uso de estos compuestos para la preparación de medicamentos
UY28846A1 (es) D-homo-17-cloro-16 (17) eno esteroides
CR8736A (es) D-homo-17-cloro-16(17)eno esteroides
CO6470855A2 (es) 17 beta-alquil-17alfa-oxi-esttratienos
CL2009001370A1 (es) Formas cristalinas de (r,s)-, (r)- y (s)-dopc; proceso de preparacion; composicion farmaceutica; y su uso para preparar medicamentos.
BRPI0402077B8 (pt) nanocápsulas contendo princípios ativos lipofílicos, uso de nanocápsulas, composições farmacêuticas e processo de preparação de nanocápsulas
ECSP003842A (es) Bases de mannich de 1-naftol y 2-naftol sustituidos, procedimiento para su preparacion, medicamentos que contienen estos compuestos, así como el uso de estos compuestos para la preparacion de medicamentos.
ECSP003597A (es) Derivados de pirrolidin - 2, 3, 4- trion -3- oxima sustituida procedimientos para su preparacion, medicamentos que contienen estos compuestos y el uso de estos compuestos para la preparacion de medicamentos
UY26617A1 (es) Derivados de 2-fenilpiran-4-ona

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160518